10x Genomics $TXG Shares Acquired by Caprock Group LLC

Caprock Group LLC raised its holdings in shares of 10x Genomics (NASDAQ:TXG - Free Report) by 59.4% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 190,913 shares of the company's stock after acquiring an additional 71,110 shares during the period. Caprock Group LLC owned approximately 0.15% of 10x Genomics worth $3,114,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also bought and sold shares of the business. AQR Capital Management LLC lifted its stake in shares of 10x Genomics by 241.3% in the 2nd quarter. AQR Capital Management LLC now owns 4,137,801 shares of the company's stock valued at $47,916,000 after purchasing an additional 2,925,372 shares during the period. Millennium Management LLC raised its position in 10x Genomics by 84.7% during the third quarter. Millennium Management LLC now owns 5,437,969 shares of the company's stock worth $63,570,000 after acquiring an additional 2,494,142 shares during the period. Wellington Management Group LLP raised its position in 10x Genomics by 126.6% during the third quarter. Wellington Management Group LLP now owns 4,285,628 shares of the company's stock worth $50,099,000 after acquiring an additional 2,394,355 shares during the period. Quantinno Capital Management LP raised its position in shares of 10x Genomics by 207.2% in the second quarter. Quantinno Capital Management LP now owns 2,233,526 shares of the company's stock valued at $25,864,000 after buying an additional 1,506,530 shares during the last quarter. Finally, JPMorgan Chase & Co. raised its position in shares of 10x Genomics by 777.6% in the third quarter. JPMorgan Chase & Co. now owns 1,073,865 shares of the company's stock valued at $12,553,000 after buying an additional 951,495 shares during the last quarter. 84.68% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

TXG has been the subject of a number of recent research reports. William Blair upgraded shares of 10x Genomics from a "market perform" rating to an "outperform" rating in a research report on Tuesday, March 31st. Bank of America lifted their price target on shares of 10x Genomics from $21.00 to $30.00 and gave the company a "neutral" rating in a research report on Monday. Deutsche Bank Aktiengesellschaft set a $17.00 price target on shares of 10x Genomics and gave the company a "hold" rating in a research report on Friday, February 13th. Citigroup raised their price objective on shares of 10x Genomics from $18.00 to $24.00 and gave the company a "neutral" rating in a research note on Tuesday, April 7th. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of 10x Genomics in a research note on Friday, March 27th. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, nine have assigned a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, 10x Genomics has an average rating of "Hold" and a consensus target price of $20.82.

Insider Activity

In other news, insider Benjamin J. Hindson sold 7,826 shares of 10x Genomics stock in a transaction on Monday, February 23rd. The shares were sold at an average price of $18.58, for a total value of $145,407.08. Following the transaction, the insider directly owned 424,779 shares of the company's stock, valued at $7,892,393.82. The trade was a 1.81% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Serge Saxonov sold 10,000 shares of the business's stock in a transaction on Monday, March 23rd. The shares were sold at an average price of $19.13, for a total transaction of $191,300.00. Following the completion of the transaction, the chief executive officer directly owned 1,177,273 shares in the company, valued at $22,521,232.49. This represents a 0.84% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 46,426 shares of company stock valued at $902,695 in the last ninety days. 9.39% of the stock is currently owned by company insiders.

10x Genomics Trading Down 6.2%

Shares of NASDAQ:TXG opened at $21.42 on Friday. The firm has a 50 day simple moving average of $21.04 and a 200-day simple moving average of $18.30. The company has a market capitalization of $2.74 billion, a PE ratio of -61.20 and a beta of 2.17. 10x Genomics has a twelve month low of $7.72 and a twelve month high of $26.44.

10x Genomics (NASDAQ:TXG - Get Free Report) last announced its earnings results on Thursday, February 12th. The company reported ($0.13) EPS for the quarter, beating analysts' consensus estimates of ($0.19) by $0.06. The business had revenue of $166.03 million for the quarter, compared to analysts' expectations of $160.35 million. 10x Genomics had a negative net margin of 6.77% and a negative return on equity of 6.89%. The company's quarterly revenue was up .6% on a year-over-year basis. During the same period in the previous year, the company posted ($0.40) EPS. As a group, equities research analysts predict that 10x Genomics will post -0.82 EPS for the current fiscal year.

10x Genomics Company Profile

10x Genomics, Inc is a biotechnology company specializing in advanced genomic analysis solutions that enable researchers to explore biology at unprecedented resolution. The company develops and manufactures integrated hardware, consumables and software products for single-cell sequencing and spatial genomics. Its flagship Chromium product line supports applications in single-cell RNA sequencing, immune profiling and genome assembly, while the Visium and Xenium platforms offer spatial transcriptomics and in situ analysis, respectively.

Founded in 2012 and headquartered in Pleasanton, California, 10x Genomics serves a global customer base that includes academic institutions, pharmaceutical and biotechnology companies, and government research organizations.

Want to see what other hedge funds are holding TXG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for 10x Genomics (NASDAQ:TXG - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.